PREDICTIVE PRESYMPTOMATIC TESTING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-52508 |   Pharmaceuticals and Healthcare

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Predictive Presymptomatic Testing Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET

7.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 23andMe Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Abbott Laboratories

16.3 Bayer HealthCare AG

16.4 Biocartis SA

16.5 BioHelix Corporation

16.6 bioMerieux S.A.

16.7 Celera Corporation (Quest Diagnostics)

16.8 Cepheid (Danaher)

16.9 Daan Diagnostics Ltd.

16.10 EKF Diagnostics Holdings plc

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Molecular Testing
Cytogenic Testing
Biochemical Testing

By Application

Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer’s Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis

Companies

23andMe Inc.
Abbott Laboratories
Bayer HealthCare AG
Biocartis SA
BioHelix Corporation
bioMerieux S.A.
Celera Corporation (Quest Diagnostics)
Cepheid (Danaher)
Daan Diagnostics Ltd.
EKF Diagnostics Holdings plc

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.